License Agreement (Details Narrative) - USD ($) $ in Thousands			1 Months Ended
	Jul. 14, 2026	Apr. 08, 2021	Jun. 30, 2025	Jun. 30, 2026	Dec. 31, 2025
Accrued license milestone				$ 50,000	$ 5,000
Pfizer License Agreement [Member]
Payment for upfront fees		$ 5,000
Pfizer License Agreement [Member] \| Common Stock [Member]
Issuance of common stock shares to Pfizer pursuant to an Equity Grant Agreement		349,406
License Agreement [Member]
Research and development expense			$ 5,000
Accrued license milestone				$ 50,000
License Agreement [Member] \| Subsequent Event [Member]
Regulatory milestone	$ 50,000
License Agreement [Member] \| Paid After FDA Filing of an NDA for Gedatolisib
Development milestone		$ 5,000
License Agreement [Member] \| Paid After FDA Approval of an NDA for Gedatolisib
Development milestone		50,000
License Agreement [Member] \| Seven Other Development Milestones
Development milestone		100,000
License Agreement [Member] \| Maximum [Member]
Aggregate value of milestone events		335,000
Development milestone		155,000
Commercial milestones		$ 180,000